The U.S. FDA has approved Novo Nordisk's Wegovy for use in lowering the risk of stroke and heart attack in overweight or obese adults who are not diabetic, the Danish drugmaker said on Friday.

Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage

Lars Fruergaard Jørgensen's remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin.

Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.

Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade.

Novo Nordisk's CEO expects more people to take obesity drugs as prices fall over time, he told Reuters on Friday, adding that new generations of the medicine will justify higher prices in some segm...

The stock move comes as Novo Nordisk, maker of obesity drug Wegovy, overtook Tesla's market value Thursday.

Novo Nordisk's CEO on Friday said compounded semaglutide in the United States is a serious health issue.

Wegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday after fresh early trial data showed positive results for its new experimental weight loss pill.

Novo Nordisk will prioritise acquisitions that can complement its pipeline of obesity and diabetes drugs rather than buying supply chain companies, the Danish group's head of business development t...

Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade.

Novo Nordisk (NYSE:NVO)'s shares are significantly overvalued, based on analysis shared by the American bank Jefferies in a note to clients. It said that, as ever, Novo delivered its 'usual polishe...

Novo Nordisk (NVO) shares opened at an all-time high after a promising weight loss trial. Jeff Pierce discusses this as Eli Lilly (LLY) shares fall after Novo Nordisk's weight loss trial shows posi...

Novo's shares have risen more than three-fold since June 2021 when it launched Wegovy in the US, last year becoming Europe's most valuable listed company, ahead of LVMH.

Novo Nordisk revealed results from a phase 1 study of amycretin at an investor event on Thursday. Patients taking the experimental drug achieved an average weight loss of 13.1% after 12 weeks.